In that study, parametric kidney MRI is being conducted and kidney oxygen consumption is being assessed by 11 C-acetate positron emission tomography
Although patients with MAFLD are expected to have abnormal liver enzymes, up to 80%, have normal liver functions in clinical practice
SGLT2i and GLP-1 RA Therapy in Type 1 Diabetes and Reno-Vascular Outcomes: A Real-World Study
There was also a positive result for the rate of nonfatal myocardial infarction events, which was lower for the albiglutide group (RR 0.75
Each pathway contributes a separate pharmacological signal: GLP-1 receptor agonism slows gastric emptying and reduces appetite signalling in the hypothalamus GIP receptor agonism enhances glucose-dependent insulin secretion and is associated in the literature with effects on lipid handling Glucagon receptor agonism increases energy expenditure and hepatic glucose output, the opposite direction to a glucagon antagonist, and is absent from every dual agonist currently on the UK market How retatrutide compares to dual agonists Tirzepatide (Mounjaro) is a GIP + GLP-1 dual agonist authorised by the MHRA for type 2 diabetes in 2023
Retatrutide is a 39-amino-acid synthetic peptide that engages three metabolic receptors simultaneously: the GLP-1 receptor, the GIP receptor, and the glucagon receptor
)
